Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Its pipeline consists of five product candidates, including potential novel therapeutics for hyperhidrosis, atopic dermatitis, allergic contact dermatitis, acne and psoriasis. Brickell's management team and board of directors have extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Brickell believes can be successful in the dermatology marketplace.
Location: United States, Colorado, Boulder
Total raised: $17M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2015 | Series C | $10M | - |
| 26.02.2013 | Series B | $7M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 02.02.2022 | 4SC pulls plug on domatinostat; Pharming says leniolisib mee... | The management board of 4SC has discontinued its domatinostat program after the most recent clinical... | endpts.com... |
| 10.11.2021 | Brickell Biotech Reports Third Quarter 2021 Financial Result... | Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide ... | marketscre... |
| 10.11.2021 | Brickell Biotech Reports Third Quarter 2021 Financial Result... | Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announ... | marketscre... |
| 07.10.2021 | Brickell Biotech : Announces Positive Topline Results, Achie... | Sofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (ND... | marketscre... |
| 01.09.2021 | Brickell Biotech : Expands Leadership Team, Appointing Dr. M... | BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Compan... | marketscre... |
| 16.08.2021 | Brickell Biotech : Announces Final Patient Completed Second ... | Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4... | marketscre... |
| 12.08.2021 | Brickell Biotech : Final patient has completed the Phase 3 p... | Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pi... | marketscre... |
| 12.08.2021 | Brickell Biotech : Reports Second Quarter 2021 Financial Res... | Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pi... | marketscre... |
| 23.07.2021 | Brickell Biotech closes on $8M fundraising round | Brickell Biotech Inc. (Nasdaq: BBI), a developer of skin disease therapies, closed on $8.05 million ... | dailycamer... |
| 22.07.2021 | Brickell Biotech : Announces $5.0 Million Bought Deal Offeri... | Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock BOULDER, CO - July 19,... | marketscre... |
Show more